Rare diseases
Investigational molecules
Locations
Ul Marcina Kasprzaka 17 A, 01-211 Warsaw, Poland
Clinical research at Instytut Matki I Dziecka includes treatment-focused studies in refractory primary bone tumors, with attention to Ewing's sarcoma, high-grade osteosarcoma, and relapsed/refractory osteosarcoma. The work is centred on improving disease control in children and adolescents with difficult-to-treat skeletal malignancies.
Research interests also extend to event-free survival and the relationship between clinical outcomes and molecular characteristics of the tumour.
Instytut Matki I Dziecka runs clinical trials in conditions such as Erdheim-Chester disease, Rosai-Dorfman syndrome, Langerhans cell sarcoma, Langerhans' cell histiocytosis, among others.
Clinical trials run by this sponsor – those enrolling participants first.
A study comparing mifamurtide to sorafenib for treating high-risk osteosarcoma in children and young adults
PolandStudy on the Effectiveness and Safety of Naxitamab for Patients with Refractory Ewing's Sarcoma
PolandStudy on Valacyclovir for Preventing and Treating Cytomegalovirus (CMV) in Pregnant Women
PolandStudy on the Effectiveness and Safety of Regorafenib for Patients with Resistant Primary Bone Tumors
PolandStudy on the Use of Fludeoxyglucose (18F) in PET/CT Scans for Young Patients with Histiocytosis
PolandStudy on Trametinib Dimethyl Sulfoxide for Children with Refractory Histiocytosis Not Responding to Conventional Treatment
PolandStudy on Vemurafenib for Children with BRAF Mutation-Resistant Histiocytosis
PolandIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
